Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Covalon Technologies Ltd.
  6. News
  7. Summary
    COV   CA22282D3022

COVALON TECHNOLOGIES LTD.

(COV)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Covalon Technologies : Announces Conference Call to Discuss Third Quarter Fiscal 2021 Financial Results

08/26/2021 | 03:50pm EDT

MISSISSAUGA, ON, Aug. 26, 2021 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q3 Fiscal 2021 financial results on Monday, August 30, 2021 before markets open. A conference call to discuss the financial results will be held on Monday, August 30, 2021 at 9:00am EST. To participate in the conference call, please dial:

North American Toll-Free: 1.888.664.6392
Local (Toronto): 416.764.8659
Confirmation Number: 01860859

A recording of the call will be available by calling 1.888.390.0541 or 416.764.8677 and entering the encore replay entry code 860859# until September 13, 2021. A recording of the call will also be available on www.covalon.com under News & Events on the Investors tab.

Copies of Covalon's financial statements and MD&A can be obtained on SEDAR at www.sedar.com and under Sedar Filings on the Investors tab of Covalon's website.

About Covalon
Covalon Technologies Ltd. is a researcher, developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives in the areas of advanced wound care, infection management and surgical procedures. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon's name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results, the impact and timing of COVID-19 on operating activities and market conditions,  and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/covalon-announces-conference-call-to-discuss-third-quarter-fiscal-2021-financial-results-301363979.html

SOURCE Covalon Technologies Ltd.

© Canada Newswire, source Canada Newswire English

All news about COVALON TECHNOLOGIES LTD.
10/18COVALON TECHNOLOGIES LTD.(TSXV : COV) added to S&P/TSX Venture Composite Index
CI
09/24Covalon Announces Retirement of Myrna Francis from Board Member
CI
09/24COVALON TECHNOLOGIES : Announces Retirement of Board Member
PR
08/30Covalon Technologies Ltd. Reports Earnings Results for the Third Quarter Ended June 30,..
CI
08/30COVALON TECHNOLOGIES : Announces Fiscal 2021 Q3 Results
AQ
08/26COVALON TECHNOLOGIES : Announces Conference Call to Discuss Third Quarter Fiscal 2021 Fina..
AQ
07/29COVALON TECHNOLOGIES : IIROC Trading Resumption - COV
AQ
07/29COVALON TECHNOLOGIES : Sells AquaGuard Product Line for US$30 Million
MT
07/29COVALON TECHNOLOGIES : Announces Sale of its AquaGuard® Product Line for US$30 Million or ..
AQ
07/29COVALON TECHNOLOGIES : IIROC Trading Halt - COV
AQ
More news
Financials
Sales 2020 25,8 M 20,8 M 20,8 M
Net income 2020 -6,95 M -5,61 M -5,61 M
Net Debt 2020 17,4 M 14,0 M 14,0 M
P/E ratio 2020 -4,44x
Yield 2020 -
Capitalization 65,9 M 53,4 M 53,2 M
EV / Sales 2019 2,00x
EV / Sales 2020 1,88x
Nbr of Employees 37
Free-Float 45,2%
Chart COVALON TECHNOLOGIES LTD.
Duration : Period :
Covalon Technologies Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COVALON TECHNOLOGIES LTD.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers and Directors
Brian E. Pedlar President, Chief Executive Officer & Director
Danny Brannagan Chief Financial Officer
Amir Boloor Chairman
Valerio DiTizio Chief Scientific Officer
Kim Crooks Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
COVALON TECHNOLOGIES LTD.130.43%53
THERMO FISHER SCIENTIFIC27.12%238 254
DANAHER CORPORATION38.87%224 750
INTUITIVE SURGICAL, INC.24.61%121 299
SIEMENS HEALTHINEERS AG39.83%76 668
EDWARDS LIFESCIENCES CORPORATION26.06%72 057